Proteolytic activity and immunogenicity of oral bromelain within the gastrointestinal tract of mice
Author:
- 1 February 2004
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 4 (2) , 255-264
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Fatal Disseminated Adenovirus Infections in Immunocompromised PatientsAmerican Journal of Clinical Pathology, 2003
- Proteolytic Inhibition ofSalmonella entericaSerovar Typhimurium-Induced Activation of the Mitogen-Activated Protein Kinases ERK and JNK in Cultured Human Intestinal CellsInfection and Immunity, 2002
- α2-Macroglobulin-Mediated Degradation of Amyloid β1–42: A Mechanism to Enhance Amyloid β CatabolismExperimental Neurology, 2001
- Prevention of Murine EAE by Oral Hydrolytic Enzyme TreatmentJournal of Autoimmunity, 1999
- Bromelain protects piglets from diarrhoea caused by oral challenge with K88 positive enterotoxigenic Escherichia coliGut, 1998
- Effects of an orally active non‐peptide bradykinin B2 receptor antagonist, FR173657, on plasma exudation in rat carrageenin‐induced pleurisyBritish Journal of Pharmacology, 1997
- Changes in CD44 Expression during Carcinogenesis of the Mouse ColonExperimental and Molecular Pathology, 1997
- Oral administration of protease inhibits enterotoxigenic Escherichia coli receptor activity in piglet small intestine.Gut, 1996
- Effect of etodolac on prostaglandin E2 biosynthesis, active oxygen generation and bradykinin formationProstaglandins, Leukotrienes and Essential Fatty Acids, 1994
- Bromelain protease F9 reduces the CD44 mediated adhesion of human peripheral blood lymphocytes to human umbilical vein endothelial cellsFEBS Letters, 1994